Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study

被引:21
|
作者
Spadea, A. [1 ]
Unim, B. [2 ]
Colamesta, V. [2 ]
Meneghini, A. [1 ]
D'Amici, A. M. [1 ]
Giudiceandrea, B. [1 ]
La Torre, G. [2 ,3 ]
机构
[1] RM A Local Hlth Unit, Rome, Italy
[2] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy
[3] Eleonora Lorillard Spencer Cenci Fdn, Rome, Italy
关键词
TIV; MF59; ATIV; Elderly; Influenza; Hospitalization; ANTIBODY-RESPONSE; HEALTH; HOSPITALIZATION; COMMUNITY; MORTALITY; CHILDREN; SAFETY;
D O I
10.1016/j.vaccine.2014.07.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Influenza illness is an important public health problem and annual vaccination is globally recommended for high risk populations. Objective: The aim was to evaluate and compare the effectiveness of influenza vaccines in reducing hospitalizations for influenza or pneumonia during two influenza seasons in the elderly. Methods: A case-control study was performed, using administrative database of the Local Health Unit Roma-A (LHU RM-A). The included subjects were at least 65 years old and residing in one of the four districts of the LHU. The cases were hospitalized for influenza or pneumonia during influenza season in the years 2010-2011 and 2011-2012. The controls were hospitalized in the same period, but not for influenza or pneumonia. The subjects were immunized with the trivalent inactivated influenza vaccine (TIV) in the first influenza season (2010-2011) and with the adjuvanted influenza vaccine MF59 (ATIV) in the second season (2011-2012). Results: A total of 269 cases and 1247 controls were included for the 2010-2011 influenza season, and 365 cases and 1227 controls were selected for the 2011-2012 season. Up to 63.6% cases and 53.5% controls in the 2010-2011 season and 78.6% of cases and 64.1% of controls in the 2011-2012 season have not been vaccinated. Female gender and high educational level were protective factors for hospitalization. Subjects over 75 years were at high risk of hospitalization compared to 65-74 years olds. Influenza vaccination reduced significantly hospitalization in both seasons. In subjects with 65-74 years TIV was more effective than ATIV; vice versa for those over 75 years old. Discussion and conclusion: TIV and ATIV reduce hospitalization for influenza or pneumonia with a variable degree of protection in different age groups. In particular, ATIV is more effective in individuals over 75 years old. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5290 / 5294
页数:5
相关论文
共 50 条
  • [21] Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons
    Boikos, Constantina
    Fischer, Lauren
    O'Brien, Dan
    Vasey, Joe
    Sylvester, Gregg C.
    Mansi, James A.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (05) : 816 - 823
  • [22] Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
    Liu, Xiaoqiang
    Park, Juliana
    Xia, Shengli
    Liang, Bin
    Yang, Shuangmin
    Wang, Yanxia
    Syrkina, Olga
    Lavis, Nathalie
    Liu, Shuzhen
    Zhao, Chenyan
    Ding, Jian
    Hu, Jieqiong
    Samson, Sandrine, I
    de Bruijn, Iris A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022,
  • [23] Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City
    Garcia-Garcia, Lourdes
    Luis Valdespino-Gomez, Jose
    Lazcano-Ponce, Eduardo
    Jimenez-Corona, Aida
    Higuera-Iglesias, Anjarath
    Cruz-Hervert, Pablo
    Cano-Arellano, Bulmaro
    Garcia-Anaya, Antonio
    Ferreira-Guerrero, Elizabeth
    Baez-Saldana, Renata
    Ferreyra-Reyes, Leticia
    Ponce-de-Leon-Rosales, Samuel
    Alpuche-Aranda, Celia
    Henry Rodriguez-Lopez, Mario
    Perez-Padilla, Rogelio
    Hernandez-Avila, Mauricio
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339 : 847
  • [24] Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study
    Treanor, John T.
    Albano, Frank R.
    Sawlwin, Daphne C.
    Jones, Alison Graves
    Airey, Jolanta
    Formica, Neil
    Matassa, Vince
    Leong, Jane
    VACCINE, 2017, 35 (15) : 1856 - 1864
  • [25] Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe
    Dieleman, Jeanne
    Romio, Silvana
    Johansen, Kari
    Weibel, Daniel
    Bonhoeffer, Jan
    Sturkenboom, Miriam
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [26] Effectiveness of Seasonal Trivalent Influenza Vaccine for Preventing Influenza Virus Illness Among Pregnant Women: A Population-Based Case-Control Study During the 2010-2011 and 2011-2012 Influenza Seasons
    Thompson, Mark G.
    Li, De-Kun
    Shifflett, Pat
    Sokolow, Leslie Z.
    Ferber, Jeannette R.
    Kurosky, Samantha
    Bozeman, Sam
    Reynolds, Sue B.
    Odouli, Roxana
    Henninger, Michelle L.
    Kauffman, Tia L.
    Avalos, Lyndsay A.
    Ball, Sarah
    Williams, Jennifer L.
    Irving, Stephanie A.
    Shay, David K.
    Naleway, Allison L.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (04) : 449 - 457
  • [27] Effectiveness of inactivated quadrivalent influenza vaccine in the 2015/2016 season as assessed in both a test-negative case-control study design and a traditional case-control study design
    Kimiya, Takahisa
    Shinjoh, Masayoshi
    Anzo, Makoto
    Takahashi, Hiroki
    Sekiguchi, Shinichiro
    Sugaya, Norio
    Takahashi, Takao
    EUROPEAN JOURNAL OF PEDIATRICS, 2018, 177 (07) : 1009 - 1017
  • [28] A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 month of age
    Pavia-Ruz, Noris
    Rodriguez Weber, Miguel Angel
    Lau, Yu-Lung
    Nelson, E. Anthony S.
    Kerdpanich, Angkool
    Huang, Li-Min
    Silas, Peter
    Qaqundah, Paul
    Blatter, Mark
    Jeanfreau, Robert
    Lei, Paul
    Jain, Varsha
    El Idrissi, Mohamed
    Feng, Yang
    Innis, Bruce
    Peeters, Mathieu
    Devaster, Jeanne-Marie
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (09) : 1978 - 1988
  • [29] Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study
    Della Cioppa, Giovanni
    Vesikari, Timo
    Sokal, Etienne
    Lindert, Kelly
    Nicolay, Uwe
    VACCINE, 2011, 29 (47) : 8696 - 8704
  • [30] Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccine in Infants A Randomized Double-Blind Placebo-Controlled Study
    Englund, Janet A.
    Walter, Emmanuel
    Black, Steven
    Blatter, Mark
    Nyberg, Jack
    Ruben, Frederick L.
    Decker, Michael D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (02) : 105 - 110